General Information of Drug (ID: DMHT84I)

Drug Name
A-216546 Drug Info
Synonyms ABT-546; (2S,3R,4S)-1-[2-(Dibutylamino)-2-oxoethyl]-2-(2,2-dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)tetrahydro-1H-pyrrole-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
71587660
CAS Number
CAS 223756-43-2
TTD Drug ID
DMHT84I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [3]
Ambrisentan DMD1QXW Pulmonary arterial hypertension BB01.0 Approved [4]
Macitentan DMP79A1 Cardiovascular disease BA00-BE2Z Approved [5]
Sparsentan DMMP51W IgA nephropathy MF8Y Approved [6]
LU302146 DMMJVXZ Pulmonary hypertension BB01 Approved [7]
Atrasentan DMM74PK Diabetic nephropathy GB61.Z Phase 3 [8]
Clazosentan DMQSBX4 Cerebral vasospasm BA85.Z Phase 3 [9]
PF-1228305 DMS1EQ7 Pulmonary hypertension BB01 Phase 3 [10]
Darusentan DMN8DQH Hypotension BA20-BA21 Phase 3 [11]
BQ-123 DM0MO8I Pulmonary arterial hypertension BB01.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endothelin A receptor (EDNRA) TTKRD0G EDNRA_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010699)
2 Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor. Eur J Pharmacol. 1999 Feb 5;366(2-3):189-201.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
7 Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
8 Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
9 Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
10 Pfizer. Product Development Pipeline. March 31 2009.
11 Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
12 Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.